secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001193125-26-003453
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes gets FDA Breakthrough Therapy designation for alixorexton in narcolepsy type 1
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy designation based on phase 1/2 data including Vibrance-1 study (n=92).
- Phase 2 met primary endpoint with dose-dependent improvements in wakefulness vs placebo.
- Alkermes plans to initiate alixorexton global phase 3 program in Q1 2026.
- Alixorexton is an investigational oral selective orexin 2 receptor agonist for NT1, NT2, and IH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526003453/0001193125-26-003453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526003453/alks-20260106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-003453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer